ArticleCurrent molecular medicine2026
Tamoxifen and Colchicine Alter Mitochondrial Respiration to Induce Cell Death in Low-metastatic Breast Cancer Cells.
Article in Current molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast cancer cells exhibit mitochondrial respiration-mediated metabolic heterogeneity and tumour aggressiveness. Tamoxifen and Colchicine are known to interfere with oxidative stress in breast cancer cells. However, their role in regulating mitochondrial respiration remains poorly understood.
methodsMCF7 and MDA-MB-231 cells were used to analyse the metabolic modulatory effects of Tamoxifen and Colchicine. The roles of Tamoxifen and Colchicine in regulating ROS production, mitochondrial membrane potential, mitochondrial membrane integrity, and oxidative phosphorylation were assessed using ROS assay, JC-1 assay, and high-resolution respirometry, respectively. Their effects on mitochondrial biogenesis and mitochondria-dependent cytotoxicity were analysed using flow cytometry and confocal microscopy.
resultsTamoxifen and Colchicine exhibited cytotoxic effects by reducing ROS production, depolarising mitochondrial membrane potential, decreasing oxygen consumption, and inhibiting mitochondrial respiration. They specifically downregulated pyruvate-mediated mitochondrial respiration, preventing N-linked state mitochondrial respiration and reducing complex I activity. Colchicine demonstrated mitochondrialindependent cytotoxic effects, whereas Tamoxifen did not. Neither drug impacted mitochondrial membrane integrity. Tamoxifen and Colchicine decreased leak respiration, inhibited proton and electron transfer, and prevented non-phosphorylating electron transfer, potentially due to reduced complex I activity. Tamoxifen significantly inhibits mitochondrial biogenesis and induces a mitochondrial-dependent cell death pathway. In contrast, Colchicine had a low impact on mitochondrial biogenesis and induced a mitochondrial-independent cell death pathway. DISCUSSION: Tamoxifen and colchicine suppress complex I-driven mitochondrial respiration in breast cancer cells, reducing oxidative phosphorylation-associated aggressiveness. Notably, only tamoxifen links this metabolic inhibition to impaired mitochondrial biogenesis and mitochondria-dependent cytotoxicity.
conclusionTamoxifen and colchicine downregulate mitochondrial respiration and biogenesis, while only tamoxifen induces mitochondrial-dependent cytotoxicity.
Indexed as
Identifiers
42755301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.